Elekta AB (EKTAY)
OTHER OTC:EKTAY
Top Page
Elekta AB
(OTC:EKTAY)
Select Model
Select Model
Rating:61Neutral
Price Target:
$6.00
▼(-5.81% Downside)
Action:ReiteratedDate:03/07/26
The score reflects mixed financial performance (profitability downshift and TTM net loss, partly offset by solid cash generation) as the biggest anchor, balanced by constructive technical momentum and a cautiously positive earnings-call outlook on orders, margins, and cost savings. Valuation is the main downside due to an extremely high P/E despite a modest dividend yield.
Positive Factors
Strong cash generation
Consistent operating and free cash flow provide durable internal funding for R&D, service execution and working-capital needs in a capital-intensive business. Strong cash conversion cushions cyclical equipment sales swings and supports debt repayment and strategic investments over months to years.
Negative Factors
Profitability deterioration
Continuing margin compression and a transition to a TTM net loss signal weaker operating leverage and reduced earnings quality. Persistently lower profitability limits reinvestment capacity, weakens returns on equity and raises dependence on cash flow to fund growth and debt servicing.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Consistent operating and free cash flow provide durable internal funding for R&D, service execution and working-capital needs in a capital-intensive business. Strong cash conversion cushions cyclical equipment sales swings and supports debt repayment and strategic investments over months to years.
Read all positive factors
Elekta AB (EKTAY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.21B
Dividend Yield0.21%
Average Volume (3M)73.00
Price to Earnings (P/E)567.4
Beta (1Y)1.30
Revenue Growth3.09%
EPS Growth-70.05%
CountryUS
Employees4,541
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)<0.01
Shares Outstanding368,587,650
10 Day Avg. Volume0
30 Day Avg. Volume73
Financial Highlights & Ratios
PEG Ratio-0.96
Price to Book (P/B)2.12
Price to Sales (P/S)1.04
P/FCF Ratio17.69
Enterprise Value/Market Cap11.08
Enterprise Value/Revenue1.44
Enterprise Value/Gross Profit3.84
Enterprise Value/Ebitda12.67
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Elekta AB Business Overview & Revenue Model
Company Description
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear ...
How the Company Makes Money
Elekta primarily makes money by selling capital equipment, software, and long-term services to healthcare providers (e.g., hospitals, cancer centers, and clinics).
1) Capital equipment sales (one-time, project-based revenue): A major revenue stre...
Elekta AB Earnings Call Summary
Earnings Call Date:Mar 05, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Jun 03, 2026
Earnings Call Sentiment Neutral
The call presented a balanced picture: clear commercial and operational positives (product approvals and launches, China recovery, improved gross margin and strong cash EBIT momentum, healthy book-to-bill and YTD cash flow improvement) alongside meaningful near-term headwinds (large FX and tariff impacts, a SEK 417m restructuring charge with further P&L effects, Americas revenue decline and some regional slowdowns). Management reiterated guidance, outlined structural cost savings (>SEK 500m run-rate) and emphasized execution of a new operating model. Given the mix of encouraging execution/operational improvements and significant external and one-time pressures, the tone is constructive but cautious.Positive Updates
Net Sales and Organic Growth
Net sales increased 2% in the quarter; organic growth was 2%. Solutions grew +1% and Service grew +3%.
Negative Updates
Significant FX Headwind
Foreign exchange movements had a material negative impact: net sales were reduced by more than SEK 500 million in the quarter (equivalent to ~-12% in growth), FX reduced gross margin by ~130 basis points and operating margin by ~180 basis points.
Read all updates
Q3-2026 Updates
Positive
Negative
Net Sales and Organic Growth
Net sales increased 2% in the quarter; organic growth was 2%. Solutions grew +1% and Service grew +3%.
Read all positive updates
Company Guidance
Management reiterated FY25/26 guidance for year‑over‑year net sales growth in constant currency and confirmed mid‑term targets remain unchanged, while guiding a total restructuring charge this year of SEK 450–500m (SEK 417m booked in Q3, ~SEK100m cash paid in Q3 and ~SEK300m remaining) and run‑rate cost savings of more than SEK 500m (mix ~30% COGS / 70% OpEx) with full effect from Q1 (1 May); Q3 metrics included net sales +2% (organic +2%), gross margin 38.3% (up 120bps despite ~100bps tariff and ~130bps FX headwinds), EBIT margin 11.9%, adjusted cash EBIT margin +170bps y/y, book‑to‑bill Q3 1.17 (rolling 12m 1.09), China book‑to‑bill >1.1 with management expecting ~10% orders and revenue growth in China in H2, FX translation reduced net sales by >SEK500m (~‑12% growth effect) and trimmed operating margin ~180bps, year‑to‑date cash flow is >SEK400m stronger and net debt is down >SEK200m versus last year, and management warned tariff and FX headwinds will persist into Q4 (with potential Middle East installation timing risks of ~2% of Q4 sales).Elekta AB Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
56
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.94B | 18.02B | 18.12B | 16.87B | 14.55B | 13.76B |
| Gross Profit | 6.36B | 6.75B | 6.80B | 6.35B | 5.44B | 5.61B |
| EBITDA | 1.93B | 2.19B | 3.29B | 2.57B | 2.69B | 3.07B |
| Net Income | -39.41M | 237.00M | 1.30B | 943.00M | 1.15B | 1.25B |
Balance Sheet | ||||||
| Total Assets | 27.88B | 28.98B | 31.41B | 29.61B | 26.30B | 24.84B |
| Cash, Cash Equivalents and Short-Term Investments | 2.56B | 2.96B | 2.78B | 3.27B | 3.07B | 4.40B |
| Total Debt | 7.34B | 7.57B | 7.25B | 6.67B | 5.70B | 6.24B |
| Total Liabilities | 19.81B | 20.13B | 20.63B | 19.88B | 17.39B | 16.65B |
| Stockholders Equity | 8.03B | 8.80B | 10.78B | 9.73B | 8.91B | 8.20B |
Cash Flow | ||||||
| Free Cash Flow | 1.71B | 1.06B | 817.00M | 400.00M | 450.00M | 1.71B |
| Operating Cash Flow | 2.62B | 2.63B | 2.46B | 1.96B | 1.86B | 2.55B |
| Investing Cash Flow | -1.13B | -1.67B | -1.92B | -1.61B | -1.65B | -613.00M |
| Financing Cash Flow | -2.27B | -607.00M | -1.10B | -129.00M | -1.73B | -3.60B |
Elekta AB Technical Analysis
Positive
6.37
Price Trends
6.12
Negative
5.98
Negative
5.48
Positive
Market Momentum
-0.10
Positive
48.35
Neutral
35.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EKTAY, the sentiment is Positive. The current price of 6.37 is above the 20-day moving average (MA) of 5.95, above the 50-day MA of 6.12, and above the 200-day MA of 5.48, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 48.35 is Neutral, neither overbought nor oversold. The STOCH value of 35.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EKTAY.
Elekta AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $44.27B | 28.46 | 6.93% | 2.13% | 8.23% | -2.04% | |
67 Neutral | $16.97B | 23.34 | 11.01% | ― | 1.74% | -25.29% | |
65 Neutral | $8.46B | 20.41 | 14.67% | 1.50% | 2.50% | 25.05% | |
64 Neutral | $9.31B | -45.07 | -17.21% | ― | -16.03% | -813.48% | |
61 Neutral | $2.21B | 567.42 | -0.45% | 0.21% | 3.09% | -70.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $8.93B | -10.24 | -13.78% | 2.75% | -21.20% | -325.40% |
* Healthcare Sector Average
EKTAY
Elekta AB
5.75
1.11
23.87%
ATR
AptarGroup
131.40
-7.49
-5.39%
BAX
Baxter International
17.30
-10.46
-37.68%
BDX
Becton Dickinson
155.46
2.57
1.68%
HOLX
Hologic
76.01
18.85
32.98%
MASI
Masimo
178.33
26.84
17.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.